Articles Tagged With: papillomavirus
-
Is HPV Testing Superior to Pap Testing Alone in Women at Risk of Cervical Cancer?
In this registry-based screening study of women in Catalonia, Spain, a negative human papillomavirus (HPV) and cytology co-test at baseline was associated with a cumulative incidence of cervical precancer of 0.4% at five years and 1.3% at nine years, compared to 27% among women with abnormal HPV testing at baseline.
-
HPV Vaccination Reduces the Risk of Invasive Cervical Cancer
In this retrospective cohort study of women in Sweden, receipt of human papillomavirus vaccination prior to age 17 years was associated with an 88% decrease in cervical cancer, and vaccination at ages 17 to 30 years was associated with a 53% decrease in cervical cancer.
-
HPV Vaccination Reduces the Risk of Invasive Cervical Cancer
In this retrospective cohort study of women in Sweden, receipt of human papillomavirus vaccination prior to age 17 years was associated with an 88% decrease in cervical cancer, and vaccination at ages 17 to 30 years was associated with a 53% decrease in cervical cancer.
-
Examining Immune Treatment for Cervical Pre-Cancers
Researchers are moving ahead with studies of a potential immunotherapeutic, nonsurgical approach to treating cervical intraepithelial neoplasia caused by human papillomavirus infection (HPV).
-
HPV Immunizations Making Mark on Disease
In a multi-year analysis of cervical precancers, data indicate that the incidence of cancers caused by human papillomavirus (HPV) types 16 and 18, which have been targeted by vaccination, has declined.
-
Providers Can Improve Teen HPV Vaccination Rates
According to a new study, only about 16% of U.S. adolescents have received the complete vaccination against human papillomavirus (HPV) by the time they turn 13 years of age, despite national recommendations for vaccination at ages 11-12.
-
Are Women Getting Screened for Cervical Cancer?
-
FDA Move Widens Approved Use of Human Papillomavirus Vaccine
The Food and Drug Administration has approved the use of the nine-valent human papillomavirus (HPV) vaccine in women and men ages 27-45. The Advisory Committee on Immunization Practices (ACIP) is scheduled to review further information at its February 2019 meeting, with a potential vote at that time. Insurance reimbursement often is based on ACIP guidance.
-
Research Focuses on Untreated Genital Warts and HIV Risk
New research indicates that genital warts may lead to a higher risk of acquiring HIV from a partner who is infected because anogenital warts may be especially susceptible to the infection.
-
Join the Mission: Increase HPV Vaccinations for Girls and Boys
The 67 National Cancer Institute-designated cancer centers and a host of other cancer organizations now are fully endorsing the goal of eliminating cancers caused by human papillomavirus (HPV) through gender-neutral HPV vaccination and evidence-based cancer screening.